Skip to main content

Magnetic Controllable Biorecognition Process of Doxorubicin Detected by Electrochemical Contact Angle Measurement

Buy Article:

$113.00 plus tax (Refund Policy)

Fe3O4 nanoparticles are the most commonly used magnetic materials with promising applications in biomedical and biochemical engineering. In this study, a novel application of the tetraheptylammonium capped Fe3O4 nanoparticles in controllable biorecognition process of anticancer drug doxorubicin through combination with external static magnetic field has been demonstrated. Our AFM and electrochemical studies illustrate that the presence of the tetraheptylammonium capped Fe3O4 nanoparticles could promote the binding behavior of doxorubicin to DNA. And the results of the electrochemical contact angle measurements indicate that the controllable biomolecular recognition of doxorubicin could be readily achieved by combining these functionalized Fe3O4 nanoparticles with changing the positions of external magnetic field.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Data/Media
No Metrics

Keywords: BIOMOLECULAR RECOGNITION; DOXORUBICIN; FE3O4 MAGNETIC NANOPARTICLES; IN SITU ELECTROCHEMICAL CONTACT ANGLE MEASUREMENT

Document Type: Short Communication

Publication date: 2007-08-01

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more